Trial Profile

A study of thiotepa, ifosphamide, etoposide and rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thiotepa (Primary) ; Etoposide; Ifosfamide; Rituximab
Indications CNS cancer; Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms TIER

Most Recent Events

01 Nov 2021 Status changed from active, no longer recruiting to completed.
17 May 2019 Planned End Date changed from 30 Jun 2021 to 31 Oct 2021.
03 Apr 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com